Researchers at UT Southwestern Medical Heart led a research revealed in JAMA Community Open which discovered that particular chemotherapies are related to an elevated long-term...
The FDA has accepted Rybrevant Faspro (amivantamab and hyaluronidase-lpuj) as the primary and solely subcutaneous, chemo-free therapy for sufferers with EGFR-mutated non-small cell lung most...
Lively Biotech has obtained optimistic suggestions from regulators on a protocol modification to its ongoing proof-of-concept scientific trial evaluating tasquinimod in sufferers with myelofibrosis, a...
Though biomarker testing in early-stage non-small cell lung most cancers has improved, some sufferers nonetheless don't obtain full, guideline-recommended testing, in keeping...
For sufferers with high-risk HER2-positive early breast most cancers who've undergone neoadjuvant remedy, therapy with Enhertu (fam-trastuzumab deruxtecan-nxki) considerably improved invasive disease-free...
Non-muscle-invasive bladder most cancers stays a illness which requires cautious consideration of varied elements when figuring out the perfect remedy method together...
